This inventor holds 1 USPTO granted patent. Top assignees: Beijing University of Technology, Novo Nordisk A/s. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2008
Title: Wei Jiang: Innovator in Peptide Purification Technology
Introduction
Wei Jiang is a notable inventor based in Victoria, Australia. He has made significant contributions to the field of peptide purification, particularly through his innovative patent. His work has implications for various applications in biotechnology and pharmaceuticals.
Latest Patents
Wei Jiang holds a patent titled "Peptide purification by means of metal ion affinity chromatography." This invention involves a polymer substrate that is functionalized with a cyclic, metal ion coordinating ligand group. The cyclic ligand group comprises at least three metal ion coordinating donor atoms, which can be independently selected from nitrogen (N), oxygen (O), and sulfur (S). This technology enhances the efficiency of peptide purification processes.
Career Highlights
Throughout his career, Wei Jiang has worked with prominent organizations, including Novo Nordisk A/S and Beijing University of Technology. His experience in these institutions has allowed him to develop and refine his innovative approaches to peptide purification.
Collaborations
Wei Jiang has collaborated with esteemed colleagues such as William Milton Thomas Hearn and Thorkild Christensen. These partnerships have contributed to the advancement of his research and the successful application of his inventions.
Conclusion
Wei Jiang's contributions to peptide purification technology exemplify the impact of innovative thinking in the scientific community. His patent and collaborations highlight the importance of advancements in biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile